Mon.Jul 08, 2024

article thumbnail

Understanding the Patient Journey: Overcoming Barriers to Enrolling Depression Clinical Trials

Worldwide Clinical Trials

By: Lisle Kingery, PhD, Therapeutic Strategy Lead, Neuroscience With depression rates at an all-time high and limited new treatments available, depression clinical trials are more important than ever. In a mental health disorder laden with patient enrollment barriers due to the indication’s symptoms, as well as many situational and social factors, how does a sponsor ensure their drug development program enrolls an adequate number of participants in a timely manner?

article thumbnail

Lilly to buy Morphic in $3B bet on inflammation drug

Bio Pharma Dive

The deal would hand Lilly an experimental pill that could one day rival Takeda's blockbuster medicine Entyvio as a treatment for inflammatory bowel disease.

Medicine 294
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Myricx Bio gains $114m in Series A round to develop NMTi-ADCs

Pharmaceutical Technology

Myricx Bio has secured £90m ($114m) in its Series A financing round to propel its NMTi-ADC therapeutics into the clinical development stage.

article thumbnail

A London biotech raises $114M to hone a new ADC payload

Bio Pharma Dive

Myricx Bio is developing a type of payload that it thinks could work in tumors resistant to the toxins contained in ADCs like Enhertu and Trodelvy.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Lilly bolsters IBD portfolio with $3.2bn Morphic acquisition

Pharmaceutical Technology

Morphic’s lead asset MORF-057 is being investigated in three IBD clinical trials, with data in ulcerative colitis expected next year.

article thumbnail

HilleVax’s norovirus vaccine ineffective in large trial of infants

Bio Pharma Dive

Shares in HilleVax plummeted after the company reported its experimental shot failed to meet the primary and secondary goals of the Phase 2b study.

More Trending

article thumbnail

NIPERs need to establish comprehensive ecosystem for entrepreneurship: DoP study

AuroBlog - Aurous Healthcare Clinical Trials blog

The National Institutes of Pharmaceutical Education and Research (NIPERs) need to establish more comprehensive ecosystem that includes mentorship, support for incubation, funding methods, and industrial alliances to promote entrepreneurship in the pharmaceutical sector, which can also substantially help these institutes to foster self-reliance, according to a study.

Research 178
article thumbnail

Ligand to buy Apeiron; Roche reports another TIGIT setback

Bio Pharma Dive

Acquiring Apeiron will hand Ligand rights to royalties on sales of the neuroblastoma drug Qarziba. Elsewhere, Aerovate said it’s considering strategic alternatives and CSL reported a notable milestone.

Sales 152
article thumbnail

Patient Safety and Radiopharmaceuticals Administration: Minimizing Radiation Exposure and Risks

Worldwide Clinical Trials

By: Anna Chwalba, MD, Senior Medical Director, Oncology & Sue Batchelor, Executive Director, Oncology Project Management In oncology, the ability to pinpoint individual cancer cells can mean the difference between making an early life-saving diagnosis or missing it entirely. With radiopharmaceuticals emerging as a diagnostic and therapeutic (theranostics) procedure, many are in the clinical development pipeline and are expected to play a crucial role in the future of healthcare.

Hormones 130
article thumbnail

Find It Hard to Focus? You May Have Cognitive Disengagement Syndrome

AuroBlog - Aurous Healthcare Clinical Trials blog

Do you find that you daydream a lot? Are you often sluggish and tend to disengage easily when doing a task? You might have cognitive disengagement syndrome, or CDS.CDS was first described by psychologists in the 1960s and 1970s when they noticed that some people display these traits more persistently than others.

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

UK pharma group reprimands Novo Nordisk for undisclosed payments

Pharmaceutical Technology

The Association of the British Pharmaceutical Industry (ABPI) also called out Novartis, Pfizer, and Otsuka for breaching its code.

147
147
article thumbnail

Lilly's Mounjao triggers more weight loss than Novo Nordisk's Ozempic: study

Fierce Pharma

Is Eli Lilly’s Mounjaro or Novo Nordisk’s Ozempic more effective in helping patients lose weight? | Is Eli Lilly’s Mounjaro or Novo Nordisk’s Ozempic more effective in helping patients lose weight? While a head-to-head trial pitting the two treatments remains ongoing, new evidence shows that Lilly’s tirzepatide may be the superior weight loss product.

article thumbnail

China’s NMPA approves Antengene’s XPOVIO for DLBCL

Pharmaceutical Technology

China's NMPA approved Antengene’s new indication of XPOVIO for adults with relapsed or refractory diffuse large B-cell lymphoma.

130
130
article thumbnail

Merck puts 1,000-plus Zostavax lawsuits to bed after plaintiffs file for dismissal

Fierce Pharma

After a drawn-out litigation process, Merck & Co. seems to have finally washed its hands of more than a thousand lawsuits tied to its shingles vaccine Zostavax. | A U.S. appeals court has tossed a request to resurrect certain lawsuits claiming Merck’s popular shot Zostavax caused patients to develop shingles. The court made its decision after the plaintiffs filed a voluntary dismissal some two years after logging a loss in Pennsylvania.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Ascentage Pharma’s olverembatinib approved in Macau for leukaemia

Pharmaceutical Technology

Ascentage Pharma has obtained approval for its new BCR-ABL1 TKI, olverembatinib, in Macau for haematological malignancy indications.

130
130
article thumbnail

With Boehringer ruling, industry extends legal losing streak against Medicare price negotiations

Fierce Pharma

As the process surrounding Medicare's drug price negotiations rolls on this summer—and as the pharmaceutical industry continues to loudly voice its complaints—another lawsuit contesting the legal v | Boehringer Ingelheim joins AstraZeneca, J&J and Bristol Myers Squibb in having a case challenging Medicare price negotiations fail to bear fruit.

Drugs 112
article thumbnail

Healthcare report finds declining public trust in institutions

pharmaphorum

A recent healthcare report conducted by Edelman reveals a concerning trend of declining public trust in healthcare institutions. Explore the key findings and implications in this comprehensive analysis.

110
110
article thumbnail

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Fierce Pharma

After announcing plans last year to expand manufacturing in its home country, Korean CDMO newcomer Lotte Biologics has kicked off work on a sprawling facility along Incheon’s waterfront near Seoul. | Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 CDMOs in the world.

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

Grifols Gets $6B Takeover Offer from Founding Family, Brookfield to Go Private

BioSpace

The blood plasma medicines manufacturer is considering a buyout offer from the founding family and asset manager Brookfield, which would delist the company from the Spanish and Nasdaq markets.

article thumbnail

Novo's Ozempic, Wegovy linked to potential eye problem? Not so fast, analysts say

Fierce Pharma

Novo Nordisk’s massively successful GLP-1 analog semaglutide, the active ingredient in the popular diabetes and obesity meds Ozempic and Wegovy, may be linked to a vision loss disorder, a new | Novo Nordisk’s popular GLP-1 analog semaglutide may be linked to a vision loss disorder, a study suggests. But one team of analysts cautioned against reading too much into the analysis.

109
109
article thumbnail

Lilly Pays $3.2B to Buy Morphic and Deepen Immunology, Gastro Portfolio

BioSpace

Eli Lilly on Monday announced a $3.2 billion all-cash deal to purchase Morphic and its pipeline of oral integrin therapies in a move to expand the pharma’s presence in the autoimmune diseases space.

108
108
article thumbnail

J&J's tuberculosis med Sirturo lands full US, EU approvals after more than a decade on the market

Fierce Pharma

It took many years, but Johnson & Johnson’s tuberculosis med Sirturo can finally claim full approvals in the U.S. and Europe following initial conditional nods. | The traditional approvals follow initial accelerated approvals granted by the FDA in 2012 and the European Commission in 2014.

Marketing 106
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

GLP-1s May Cut Risk of 10 Obesity-Related Cancers in Diabetes Patients: Study

BioSpace

GLP-1 receptor agonists could reduce the risk of 10 obesity-associated cancers, such as meningioma, multiple myeloma and colorectal cancer, in type 2 diabetes patients, according to an analysis of electronic health records.

108
108
article thumbnail

Roche to reintroduce eye implant med Susvimo 2 years after recall

Fierce Pharma

Roche's launch of eye implant Susvimo was stopped short in 2022 after manufacturing concerns led to a market withdrawal. Now, with the FDA’s blessing to reintroduce the therapy, the | The company is reintroducing the therapy after receiving the FDA's blessing for updates made to the device, ending a two-year voluntary recall.

article thumbnail

Myricx Bio Raises $115M in Series A to Advance ADC With Lilly and Novo Backing

BioSpace

The U.K.-based biotech is the latest to cash in on the hot antibody-drug conjugate space, closing a $115.5 million Series A round co-led by Novo Holdings and with participation from Eli Lilly.

Antibody 104
article thumbnail

Study finds GLP-1 drugs may cut obesity-related cancers

pharmaphorum

GLP-1 agonists like Novo Nordisk's Ozempic reduce the risk of 10 of 13 cancers associated with obesity in an observational study.

Drugs 114
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Boehringer Ingelheim Loses Legal Challenge to IRA in Federal Court Ruling

BioSpace

A federal judge ruled last week that the U.S. government can use its economic standing as a bulk drug purchaser to negotiate for better deals, handing Boehringer Ingelheim a loss in its legal challenge to the Inflation Reduction Act.

Drugs 100
article thumbnail

Myricx raises £90m after pivot to ADCs for cancer

pharmaphorum

Myricx Bio taps into the red-hot interest in companies working on antibody-drug conjugates (ADCs) for cancer, raising £90m in its Series A

Antibody 111
article thumbnail

Roche Axes Phase II/III NSCLC Study as TIGIT Drug Loses to Keytruda-Chemo Combo

BioSpace

Roche’s tiragolumab, when combined with its PD-L1 blocker Tecentriq, did not significantly improve progression-free and overall survival versus Keytruda and chemotherapy in patients with non-small cell lung cancer.

Drugs 98
article thumbnail

Lilly scores against Novo Nordisk in weight loss contest

pharmaphorum

An observational study has suggested that Lilly’s tirzepatide is better at achieving weight loss than Novo Nordisk's semaglutide

111
111
article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.